MedTrace Logo

MAP Study: Methotrexate and Adalimumab in Psoriasis

NCT03217734 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2019-07-09

No results posted yet for this study

Summary

Assess the efficacy and safety of ADA compared to ADA/MTX in patient with Psoriasis. Compare Anti-ADA antibody formation and serum ADA levels in patients on ADA compared with those on combination ADA and MTX.

Conditions

Interventions

BIOLOGICAL

Adalimumab

Subcutaneous Injection

DRUG

Methotrexate

Oral Tablet

DRUG

Placebo

Oral Tablet

Sponsors & Collaborators

  • AbbVie

    collaborator INDUSTRY

  • Jeffrey J Crowley MD

    lead INDUSTRY

Principal Investigators

  • Jeffrey J Crowley, MD · Bakersfield Dermatology and Skin Cancer Medical Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-04-10
Primary Completion
2018-12-31
Completion
2018-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03217734 on ClinicalTrials.gov